Evidence map›Paper›PMID 41445600›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Learning Patient Similarity from Genomics for Precision Oncology.

Maha Shady, Brendan Reardon, Sharon Jiang, Erica Pimenta, Tess O'Meara, Jihye Park, Kenneth L Kehl, Haitham A Elmarakeby, Shamil R Sunyaev, Eliezer M Van Allen

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maha ShadyDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Brendan ReardonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sharon JiangDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Erica PimentaDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Tess O'MearaDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kenneth L KehlDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Haitham A ElmarakebyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shamil R SunyaevDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Eliezer M Van AllenDepartment of Medicine, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0201-4444

Funding

The origin, the function and the phenotypic impact of human allelesR35GM127131 · NIGMS · HARVARD MEDICAL SCHOOL · PI SHAMIL SUNYAEV · 2018 to 2026
$8.1M
Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney CancerR01CA278980 · NCI · DANA-FARBER CANCER INST · PI Eliezer M Van Allen · 2024 to 2026
$2.1M
Molecular origins and evolution to treatment resistance in genitourinary cancersR50CA265182 · NCI · DANA-FARBER CANCER INST · PI Jihye Park · 2022 to 2026
$1.7M
NCI NIH HHS R01 CA278980NCI NIH HHS R50 CA265182NIGMS NIH HHS R35 GM127131
6 · The paper itself

Abstract

Introduction: Precision oncology has informed cancer care by enabling the discovery and application of diagnostic, prognostic, and/or predictive molecular biomarkers. However, many patients lack actionable biomarkers or fail to respond to biomarker-directed therapies. Patient similarity approaches can leverage comprehensive tumor profiling and prior clinical experiences from large cohorts for decision support, facilitating broader realization of precision oncology insights. Methods: We developed a deep learning-based modeling framework using real-world clinicogenomic data from a tertiary cancer center to (i) measure patient similarity based on embedded tumor genomic profiles and (ii) evaluate the association of derived patient subgroups and neighborhoods with shared therapeutic outcomes in breast cancer-specific and histology-agnostic pan-cancer settings. Results: The model recovered clinically meaningful patient clusters reflecting both expected and previously unknown therapeutic associations, as well as patient-specific neighborhoods that could inform therapeutic trajectories more often than expected by chance in multiple clinical contexts. Moreover, model utility extended to patients without actionable genomic biomarkers and those with cancer of unknown primary (CUP) diagnoses, where neighborhoods aligned with independently predicted primary cancer type. These neighborhoods could also be examined over time in a continuously learning scenario. Conclusion: This similarity-based modeling framework distilled complex molecular and clinical data into concise, context-specific insights that augment clinician judgment, providing a foundation for a real-time learning, patient-centered decision support model in precision oncology.

Identifiers

PMID41445600
PMCPMC12723981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.